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Abstract
Background: Sequencing of the human genome has led to most genes being available in BAC or
PAC vectors. However, limited functional information has been assigned to most of these genes.
Techniques for the manipulation and transfer of complete functional units on large DNA fragments
into human cells are crucial for the analysis of complete genes in their natural genomic context.
One limitation of the functional studies using these vectors is the low transfection frequency.
Results: We have constructed a shuttle vector, pPAC7, which contains both the EBNA-1 gene and
oriP from the Epstein-Barr virus allowing stable maintenance of PAC clones in the nucleus of human
cells. The pPAC7 vector also contains the EGFP reporter gene, which allows direct monitoring of
the presence of PAC constructs in transfected cells, and the Bsr-cassette that allows highly efficient
and rapid selection in mammalian cells by use of blasticidin. Positive selection for recombinant PAC
clones is obtained in pPAC7 because the cloning sites are located within the SacBII gene. We show
regulated expression of the CDH3 gene carried as a 132 kb genomic insert cloned into pPAC7,
demonstrating that the pPAC7 vector can be used for functional studies of genes in their natural
genomic context. Furthermore, the results from the transfection of a range of pPAC7 based
constructs into two human cell lines suggest that the transfection efficiencies are not only
dependent on construct size.
Conclusion: The shuttle vector pPAC7 can be used to transfer large genomic constructs into
human cells. The genes transferred could potentially contain all long-range regulatory elements,
including their endogenous regulatory promoters. Introduction of complete genes in PACs into
human cells would potentially allow complementation assays to identify or verify the function of
genes affecting cellular phenotypes.
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Sequencing of the human genome has led to most genes
being available in F-plasmid based and P1-derived bacte-
rial artificial chromosomes (BACs/PACs) [1-5]. Even
though the genome projects have resulted in the discovery
of a large number of genes, limited functional informa-
tion has been assigned to most of these genes. One
approach to analyze the biological functions of genes is
direct introduction of complete genes into appropriate
cells to monitor the phenotypic effects of the gene or its
mutated versions. The average mammalian gene has been
estimated to span 50 kb, and sequences distant from the
gene itself are often important for proper developmental
and tissue-specific expression [6]. Furthermore, constructs
containing complete genes including introns have shown
stable expression and facilitate physiological expression
levels and tissue-specific expression patterns [7,8]. There-
fore, techniques for the manipulation and transfer of
complete functional units on large DNA fragments into
human cells are crucial for the analysis of complete genes
in their natural genomic context.
Plasmid vectors based on EBV are stably maintained extra-
chromosomally over long periods of time, although segre-
gation of the vectors to daughter cells upon cell division is
random rather than equal [9,10]. The functional compo-
nents of such vectors are the EBV latent origin of replica-
tion (oriP) [11], which interacts with the viral
transactivator protein EBNA-1 [12] to promote episomal
maintenance. Functional studies using BACs have been
performed in hamster cells [13], transgenic mice [14,15],
and in human cells [16]. BAC vectors with oriP/EBNA-1
have successfully been used for introduction of large
transgenes into mammalian cells and several studies have
demonstrated the general utility of the oriP/EBNA-1 sys-
tem in mammalian cells [9,16-27].
We have constructed the pPAC7 shuttle vector to facilitate
the use of large-insert bacterial clones (BACs/PACs) as
oriP/EBNA-1 episomes for functional analysis of complete
genes in human cell lines. Our vector carries the Enhanced
Green Fluorescent Protein (EGFP) reporter gene, which
allows direct monitoring of transfected cells for the pres-
ence of PACs. We document regulated expression of the
CDH3 gene carried as a 132 kb genomic insert cloned into
pPAC7, demonstrating that the pPAC7 vector can be used
for functional studies of genes in their natural genomic
context. Even though the BAC/PAC vectors can be used to
introduce large genomic fragments into human cells, the
large size of these DNA constructs has provided challenges
to their use as experimental or therapeutic materials. One
of these challenges is the inefficient transfection of large
DNA constructs. When introducing constructs ranging in
size from 23,4 kb to 155 kb into human cell lines a direct
relationship between construct size and transfection effi-
ciency was not detected.
Results & Discussion
The functionality of the shuttle vector pPAC7
A detailed description of the vector pPAC7 [GenBank:
FJ710109] is given in the Methods section, and a map of
the vector is shown in Figure 1A. The pUC-link fragment
in pPAC7, which separates the SacBII gene from its pro-
moter is removed in the PAC construction process. The
SacBII gene product converts sucrose to levan, which is
toxic to the host cells. During PAC construction, large
DNA fragments replace the stuffer fragment maintaining
the separation of the promoter and the coding region of
the SacBII gene, thus resulting in positive selection for
recombinant PAC clones [28]. pPAC7 also contains the
attTn7 sequence, permitting highly specific Tn7 mediated
insertion of sequence elements into the vector portion of
the pPAC7 vector for tailor-made functional analysis of
genes carried on the cloned inserts [28]. Specific lineariza-
tion of the PACs can be achieved by using the lambda ter-
minase or the PI-SceI enzyme cleaving in the vector cos
site or PI-SceI respectively [28].
In order to verify the functionality of the elements
included in pPAC7, the vector was transfected into the cell
line SK-BR-3. The increasing fraction of viable EGFP
expressing cells, that was obtained when grown in media
containing increasing concentrations of blasticidin, dem-
onstrated the presence of functional Bsr and EGFP gene
cassettes in pPAC7 (Figure 1B). SK-BR-3 cells transfected
with either pEGFP-C1 or pPAC7 were sorted by flow
cytometry for EGFP, resulting in a cell population con-
taining 95% EGFP expressing cells. The percentage of
EGFP expressing cells remained high and the number of
EGFP positive cells increased when SK-BR-3 cells trans-
fected with pPAC7 were grown in non-selective medium
(Figure 1C). Control cells transfected with a non-replicat-
ing vector, pEGFP-C1, showed no increase in the number
of EGFP positive cells (Figure 1C). The fact that the pPAC7
vector is being replicated and distributed to daughter cells
demonstrates the funtionality of the OriP/EBNA-1 system.
The high number of EGFP positive cells after transfection
with pPAC7 was also visualized by microscopy 15 days
after sorting and growth in non-selective medium (Figure
1D). Note that not only are more cells positive for EGFP
after transfection with pPAC7, but the fluorescence inten-
sity is three fold lower in pEGFP-C1 transfected cells (cam-
era shutter time: 1306 ms) compared to pPAC7
transfected cells (camera shutter time: 390 ms). The differ-
ence in intensities may indicate the presence of variable
copy numbers of pPAC7, which is expected for oriP/
EBNA-1 episomes [9,17]. Also OriP is known to act as an
transcriptional enhancer in the presence of the EBNA-1
protein, which also can account for the increased fluores-
cence in the pPAC7 transfected cells [29]. In summary,
these results verify that the Bsr, EGFP, oriP and EBNA-1
elements are functional in the pPAC7 vector.Page 2 of 9
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pPAC7
It has previously been shown that both alleles of the
CDH1 gene is deleted in the SK-BR-3 cell line [30]. We
demonstrate that the deletion extends more than 100 kb
upstream of CDH1, covering all the exons of CDH3 and at
least 10 kb upstream of this gene (Figure 2). Since the SK-
BR-3 cell line is completely lacking the CDH3 gene, and
CDH3 has been shown to be regulated by steroids [31],
we chose to use this gene to demonstrate regulated gene
expression from the pPAC7 vector. In order to express the
CDH3 gene within its native genomic context, the com-
plete gene, including all exons, introns and 32 kb
upstream sequence was transferred as a 132 kb fragment
into pPAC7 (see Methods). This construct, pPAC7-CDH3,
was transfected into SK-BR-3 and the cells grown in selec-
The pPAC7 vectorFigure 1
The pPAC7 vector. A) Schematic map of the pPAC7 vector which contains the EGFP gene cassette (EGFP), the blasticidin 
deaminase gene cassette (Bsr), the EBNA-1 gene cassette (EBNA-1), and the Epstein Barr virus origin of replication (oriP). The 
pUC-link fragment is removed by BamHI or NotI digestion during the cloning process and replaced by large genomic DNA frag-
ments allowing positive selection for recombinant clones on sucrose containing media due to the SacBII gene present on the 
vector. The kanamycin resistance gene (Kan(R)) is a bacterial selection marker. The NotI restriction sites are used when verify-
ing the different constructs. B) SK-BR-3 cells were transfected with pPAC7 and grown in the presence of blasticidin using the 
concentrations indicated. The percent of EGFP positive cells, from all viable cells, were measured by flow cytometry after 2, 4 
and 6 days. The experiments were performed in triplicates with standard deviations shown. C) SK-BR-3 cells transfected with 
pPAC7 or pEGFP-C1 were sorted by flow cytometry and grown in non-selective medium. The percentage and total number of 
EGFP expressing cells was measured by flow cytometry 4, 11 and 15 days after cell sorting. The experiments were performed 
in triplicates with standard deviations indicated. D) The fluorescent microscopy pictures show the SK-BR-3 cells transfected 
with pEGFP-C1 and pPAC7 15 days after cell sorting. The shutter time is 1306 ms for pEGFP-C1 transfected and 390 ms for 
pPAC7 transfected cells.Page 3 of 9
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SK-BR-3/pPAC7-CDH3, carried the CDH3 fragment (Fig-
ure 2, see additional file 1 for list of primers). Because
pPAC7 replicates (Figure 1), we assume that the construct
pPAC7-CDH3 is maintained as an episome in this cell
population.
To verify transcription of CDH3 in the SK-BR-3/pPAC7-
CDH3 cell population we performed Real Time PCR (Fig-
ure 3A). As expected, the parent SK-BR-3 cell line showed
no endogenous CDH3 expression. Since the CDH3 tran-
script was detected in the SK-BR-3/pPAC7-CDH3 cells
using an assay which spans sequences in exon 12, 13 and
14, this strongly suggests that correct transcription and
splicing of CDH3 was obtained in these cells.
When the breast cancer cell line MCF-7 is grown in media
with charcoal stripped FBS and without phenol red, a clear
increase in CDH3 expression is observed compared to
cells grown in regular medium (Figure 3B). This difference
in expression can most probably be explained by the pres-
ence of steroids in the latter medium, which are known to
suppress CDH3 expression [31]. Decreased CDH3 expres-
sion was also detected when SK-BR-3/pPAC7-CDH3 cells
were grown in media containing phenol red and regular
FBS (Figure 3B). In total, these results demonstrate regu-
lated CDH3 expression when the pPAC7-CDH3 construct
carrying the complete gene is introduced into the human
cell line SK-BR-3. Thus, constructs in pPAC7 provide
important tools in functional experiments, including the
identification and validation of candidate disease genes.
Transfection efficiency and construct size
There is conflicting evidence on whether construct size
directly affects the efficiency of transfection into mamma-
lian cells [32-35]. Using pPAC7, pPAC7-39 and pPAC7-
CDH3 provided us with plasmids in a size range from
23,4 kb to 155 kb (Figure 4A), all expressing the EGFP
reporter gene under the control of the same promoter.
These constructs were transfected into 293T and SK-BR-3
Stable maintenance of pPAC7 in SK-BR-3 cellsFigure 2
Stable maintenance of pPAC7 in SK-BR-3 cells. Schematic presentation of the CDH3 and CDH1 genes with the positions 
on human chromosome 16q22.1 shown in Mb. The 132 kb insert cloned in pPAC7-CDH3, and the positions of the PCR prim-
ers used are indicated. DNA isolated from the 293T, SK-BR-3 (S), SK-BR-3/pPAC7 (S-pPAC7) and SK-BR-3/pPAC7-CDH3 (S-
CDH3) cell lines was amplified by PCR using the primers indicated [see Additional file 2]. In these experiments the control 
primers in the NAE1 gene gave a PCR product both from SK-BR-3 and 293T, while no products were detected from SK-BR-3 
using the 3 primer pairs from the CDH1-CDH3-region. Selected fragments in the GeneRuler™ 100 bp DNA Ladder (Fermen-
tas, MD, USA) are indicated.Page 4 of 9
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ured by flow cytometry.
A decreasing fraction of EGFP positive cells were detected
with increasing construct size (results not shown). How-
ever, since the DNA mass is a critical parameter for trans-
fections, a fixed mass of DNA from each construct was
used in these experiments. When the transfection efficien-
cies are normalized with respect to the molar concentra-
tions of plasmid DNA (Figure 4B), a decrease in
transfection efficiency with increasing plasmid size was
observed in 293T. However, this tendency was not distinct
in SK-BR-3. The decreased transfection efficiency with
increasing plasmid size detected in 293T might be due to
the smaller number of plasmid molecules delivered to the
cells when transfecting large plasmids compared to
smaller ones. This is in agreement with McLenachan and
co-workers [35] who concluded that cellular uptake is
largely independent of DNA size.
In the present work the transfected cells showed decreased
fluorescence intensities with increasing plasmid size (Fig-
ure 4C). This is in agreement with previous observations
that cells successfully transfected by larger plasmids show
lower level of marker gene expression than those trans-
fected with smaller plasmids [33,34]. It has been sug-
gested that large plasmids are more susceptible to
degradation within the cell because the mobility through
the cytoplasm decreases with increasing plasmid size [35].
Thus decreased marker expression with increasing plas-
mid size could be a result of lower copy number in the
nucleus of cells transfected with the large constructs. This
effect may also explain the decrease in luciferase levels in
the cell populations previously reported by Kreiss and co-
workers [32]. In conclusion, our results support the
hypothesis that cellular uptake of large DNA constructs in
human cell lines is not only dependent on DNA size.
Conclusion
We present an EGFP reporter PAC shuttle vector, pPAC7,
which can serve as an important tool in functional studies,
one application being validation of candidate disease
genes. After introduction of a 132 kb fragment containing
the complete CDH3 gene in its native genome context, we
show regulated expression of the gene carried on the con-
struct. We also performed transfection experiments with a
series of vectors in the size range 23,4 kb to 155 kb, and
detected no apparent correlation between construct size
and transfection efficiency.
Regulated CDH3 expression from pPAC7-CDH3 in SK-BR-3Fig re 3
Regulated CDH3 expression from pPAC7-CDH3 in SK-BR-3. A) Real Time PCR experiments showing relative endog-
enous CDH3 expression in selected cell lines. B) The CDH3 expression levels in the cell population SK-BR-3/pPAC7-CDH3 
(CDH3 transgene) and in MCF-7 (endogenous) are decreased when grown in regular media (FBS/PR) (+) compared to the cells 
grown media without phenol red containing charcoal stripped FBS (-).Page 5 of 9
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Vector construction
This report describes a bacterial artificial chromosome
vector, pPAC7 [GenBank: FJ710109], which was con-
structed from two precursor vectors, pE106 and pPAC3.2,
used in the construction of pPAC4 [28]. The plasmid
pE107 was made by replacing the hCMV-cassette from
pE106 with an adapter (ctagtgtcgactttacgcgtg), introduc-
ing unique SalI and MluI sites between the SpeI and BstEII
sites in pE106. The EBNA-1 gene was obtained as a SpeI
fragment from the vector pEBAC1602-3 (kindly provided
by Dr. Panos Ioannou, The Murdoch Children's Research
Institute) and cloned into pE107, resulting in the vector
pE108. pE108, containing EBNA-1, the Bsr Cassette, and
the lambda cos site, was digested with NheI and BstEII and
ligated to NheI/BstEII digested pPAC3.2. The clone con-
taining the correct sequence elements was named pPAC5.
The EGFP gene was first transferred from the pEGFP-C1
vector (Clontech Laboratories, Palo Alto, CA, USA) into
Transfection efficiencies measured in 293T and SK-BR-3 cellsFigur  4
Transfection efficiencies measured in 293T and SK-BR-3 cells. A) DNA from each of the constructs pPAC7, pPAC7-
39 and pPAC7-CDH3 was digested with NotI and separated on a BioRad CHEF-mapper. During construction of pPAC7-39 one 
of the NotI restriction sites got deleted and thus giving a linearised fragment when digested with NotI. Selected fragments in the 
Low Range PFG Marker are indicated. B) Diagram showing the fraction of viable, EGFP-expressing 293T and SK-BR-3 cells 
measured by flow cytometry the day after the transfection with the following constructs: pPAC7, pPAC7-39 and pPAC7-
CDH3. One μg of DNA from each construct was used for transfection, and the figure shows the transfection frequencies nor-
malized with respect to the molar concentrations of plasmid DNA used in each transfection. For the 293T cell line, each bar 
represents three independent experiments all performed in triplicate. For the SK-BR-3 cell line each bar represents two sepa-
rate experiments, both performed in triplicates. Standard deviations are indicated. C) Representative flow diagrams showing a 
10-fold decrease in EGFP intensities in the 293T cell line with increasing plasmid size. Constructs used are: pPAC7, pPAC7-39 
and pPAC7-CDH3.Page 6 of 9
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loxP511 and the PI-SceI site [28]. Then a BssHII-fragment
from pE103-EGFP containing the EGFP and oriP genes
was ligated to a pPAC5 AscI fragment. A clone containing
the correct sequence elements was named pPAC7. All
cloning intermediates were analyzed by restriction digests
and sequenced using the appropriate primers [see Addi-
tional file 2].
Cloning the complete CDH3 gene into pPAC7
The PAC clone RPCI6-77A18 has previously been shown
to contain the complete CDH3 gene [36]. The 132 kb
insert in this clone was transferred to the vector pPAC7 as
a NotI-fragment. Colonies obtained in this cloning step
were screened by PCR [see Additional file 1]. Positive
clones were analyzed by PFGE and sequencing over the
cloning junctions [see Additional file 1]. The construct
containing the complete 132 kb insert was named pPAC7-
CDH3 (see Figure 2). A smaller PAC-construct was also
made in this cloning process by transferring a 18,5 kb NotI
fragment into pPAC7. The size of this construct, named
pPAC7-39, was verified by PFGE.
Growth and transfection of mammalian cells
The 293T cell line (ATTC CRL 11268), which is an adeno-
virus transformed primary human embryonic kidney cell
line expressing the SV40 large T antigen, and the human
mammary adenocarcinoma cell line, SK-BR-3 (ATTC
HTB-30) and its derivatives were grown in RPMI1640
with phenol red (Bio Whittaker, MD, USA) supplemented
with 2 mM L-glutamine and 10% FBS (Gibco BRL®, CA,
USA). For experiments related to the functional studies of
CDH3, the human mammary adenocarcinoma cell lines
MCF-7, SK-BR-3 and its derivatives, the human mammary
ductal carcinoma cell line ZR-75-1, 293T and 293E (293T
stably expressing the Epstein-Barr virus nuclear antigen),
were grown in RPMI1640 without phenol red (Gibco
BRL®, CA, USA) supplemented with 25 mM Hepes (Gibco
BRL®, CA, USA), 10% charcoal-stripped FBS (Innovative
Research, MI, USA) and 2 mM L-Glutamine (Gibco BRL®,
CA, USA).
Transfections were performed using a ratio of 10:4 of the
Lipofectamine 2000 (Invitrogen, CA, USA) reagent (μl) to
DNA (μg). Cells were plated in 6 well plates at a density of
6 × 105 cells per well, 24 hours prior to transfection. All
experiments were performed in triplicate. In experiments
where selection was applied, medium containing 2, 5 and
10 μg/ml blasticidin (InvivoGen CA, USA) was added 2
days after transfection of the SK-BR-3 cell line.
Pictures of transfected cells were taken using a Zeiss Axio-
vert 200 M microscope, and the data processed using the
Axio Vision 3.1 program. Black and white pictures show-
ing the cell population and pictures showing the fluores-
cent cells were compared.
Flow cytometry
Flow cytometry was performed using a Becton Dickinson
dual-laser FACScalibur analysis instrument (BD Bio-
sciences, CA, USA) and the Cell Quest software. Cells were
harvested 24 hours after transfection by adding trypsin-
EDTA. The cell suspension (500 μl) was mixed with a
pipette and filtered through a filter cloth (50 μm, Eiolf
Thon) into Falcon sample tubes. 1 μl propidium iodide (1
mg/ml) was added to the cell suspensions before the sam-
ples were analyzed.
Cell sorting was performed using a Becton Dickinson tri-
ple-focus Diva. The samples were prepared as described
for flow cytometry. The sorted cells were plated in a 12
well plate.
Relative quantification of CDH3 expression
Total RNA from cells harvested in 1× Nucleic Acid Purifi-
cation Lysis Solution (Applied Biosystems, Foster City,
CA, USA) was extracted on the ABI PRISM® 6100 Nucleic
Acid PrepStation (Applied Biosystems, Foster City, CA,
USA) using the Cultured Cells kit (Applied Biosystems,
Foster City, CA, USA). The RNA was reverse transcribed
using the High Capacity cDNA Archive Kit (Applied Bio-
systems, Foster City, CA, USA), and cDNA synthesis was
performed on a Gene Amp® PCR system 9700 (Applied
Biosystems, Foster City, CA, USA), programmed with an
initial step at 25°C for 10 minutes, followed by 37°C for
2 hours and 85°C for 5 seconds.
For real-time quantification of relative gene expression,
Applied Biosystems' ABI PRISM 7900 HT Sequence Detec-
tion System was used at the following conditions: 50°C
for 2 minutes, 95°C for 10 minutes followed by 40 cycles
with 95°C for 15 seconds and 60°C for 1 minute. All rea-
gents were purchased from Applied Biosystems; TaqMan
Universal PCR Master Mix and the TaqMan Gene Expres-
sion Assays: CDH3 (Assay ID: Hs_00999916_m1), and
PMM1 (Assay ID: Hs_00963625_m1). The quantification
of cDNA was performed using the comparative CT
method (Livak and Schmittgen, 2001), where the amplifi-
cation of the target (CDH3) and endogenous control
(PMM1) was run in separate tubes. The amount of target
was calculated by normalization to an endogenous con-
trol, relative to a calibrator sample (Stratagene® QPCR
Human Reference Total RNA, Cat. No. 750500, Strata-
gene, La Jolla, CA, USA).
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